BFRM Bioform Medical (MM)

SAN MATEO, Calif., Nov. 7 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (NASDAQ:BFRM) today announced the initial public offering of 10,000,000 shares of common stock at a price of $8.00 per share. BioForm has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the initial public offering price to cover over-allotments, if any. The common stock will trade on the Nasdaq Global Market under the symbol "BFRM." J.P. Morgan Securities Inc. and Piper Jaffray & Co. are serving as joint book-running managers for the offering, with CIBC World Markets Corp. and Jefferies & Company, Inc. serving as co-managers. A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A copy of the final prospectus for the offering may be obtained from the prospectus department of either J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, or by calling (718) 242-8002; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling (877) 371-5212. About BioForm Medical, Inc.: BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm's products include Radiesse(R), a long-lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation. BioForm has licensed U.S. marketing rights to Aethoxysklerol(R), the worldwide leading sclerotherapy agent, which is currently being evaluated in a Phase III clinical trial. BioForm has also licensed BioGlue, a new surgical adhesive product for plastic surgery applications, which is being developed in a partnership with CryoLife, Inc. Contact: Adam Gridley 650/286-4025 Vice President, Corporate Development BioForm Medical, Inc. DATASOURCE: BioForm Medical, Inc. CONTACT: Adam Gridley, Vice President, Corporate Development of BioForm Medical, Inc., +1-650-286-4025 Web site: http://www.bioformmedical.com/

Copyright